Whitehawk closes sale of Aadi Subsidiary for $102.4M; pro forma cash $131M; FY2024 pro forma loss $25.2M

Whitehawk Therapeutics, Inc.

Sale closed March 25, 2025; total cash proceeds of $102.4M after purchase-price adjustments.
Pro forma balance sheet as of Dec 31, 2024 shows cash & equivalents of $131.1M.
Estimated gain on sale of $93.2M recorded; pro forma FY2024 net loss improves to $25.2M from historical $63.7M.
Aadi revenue ($26.0M) and operating expenses ($64.3M) removed from pro forma statement.
Stockholder approval obtained February 28, 2025; company retains no FYARRO program revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.